Yıl 2020, Cilt 3 , Sayı S1, Sayfalar 63 - 67 2020-05-15

COVID-19 ve Hemoglobinopatiler
COVID-19 and Hemoglobinopathies

Ali FETTAH [1] , Zeynep KARAKAŞ [2]


Yeni koronavirüs hastalığı (COVID-19) ilk olarak 2019'un sonunda bildirildi. Hastalık birkaç ay içinde hızla tüm dünyaya yayıldı ve Mart 2020'de Dünya Sağlık Örgütü tarafından dünya çapında bir salgın olarak ilan edildi. COVID-19 üst solunum yolu enfeksiyonu veya pnömoni gibi solunum yolu enfeksiyonlarına neden olan bir hastalıktır. İleri yaş grubunda ve altta yatan hipertansiyon, diabet, kardiyovasküler hastalık, kanser, kronik akciğer hastalığı, ve kronik böbrek hastalığı gibi komorbiditesi olanlar ağır hastalık tablosu için risk oluşturmaktadır. Bu yüzden orak hücreli anemi ve talasemi gibi sık komorbidite görülen hemoglobinopatilerde COVID-19'un nasıl seyredeceği net olarak bilinmemektedir. Bu derlemede halen kısıtlı bilgilere ulaşabildiğimiz ve bilinmezliği devam eden COVID-19’un orak hücreli anemi ve talasemi hastalarındaki durumunun irdelenmesi amaçlanmıştır.
The novel coronavirus disease (COVID-19) was firstly reported at the end of 2019. The disease rapidly spread all around the world in a few months and was declared a worldwide pandemic by World Health Organisation in March 2020. COVID-19 causes respiratory tract illness that may generally occur as mild upper respiratory tract disease or pneumonia. Older patients and those with pre-existing medical conditions such as hypertension, diabetes, cardiovascular disease, cancer, chronic lung disease and chronic kidney disease have been identified as populations at risk of a severe disease course. Therefore, it is not clear how COVID-19 will progress in hemoglobinopathies such as sickle cell anemia and thalassemia, which are common comorbidity. In this review, it is planned to examine the condition of COVID-19, in which we still have limited information and remains unknown, in sickle cell anemia and thalassemia patients.
  • 1. T.C. Sağlık Bakanlığı (2020). COVID-19 (SARSCoV-2 Enfeksiyonu) Rehberi. Website: https:// covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_ Rehberi.pdf (erişim: 23.04.2020)
  • 2. Tufan A, Avanoğlu Güler A, Matucci-Cerinic M .COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci. 2020 Apr 21;50(SI-1):620-632.
  • 3. Taher AT, Weatherall DJ, Capellini MD. Thalassaemia. Lancet 2018;391:155-67.
  • 4. Ricerca BM, Di Girolamo A, Rund D. Infections in thalassemia and hemoglobinopathies: focus on therapy-related complications. Mediterr J Hematol Infect Dis. 2009 Dec 28;1(1):e2009028.
  • 5. Thalassaemia International Federation. The COVID-19 Pandemic and Haemoglobin Disorders. Website: https://thalassaemia.org.cy/wp-content/ uploads/2020/03/COVID-19-pandemic-andhaemoglobin-disorders_V3.pdf. (Accessed: 23.04.2020)
  • 6. British Society for Haematology. Advice on COVID-19 in patients with Sickle Cell Disease and Thalassaemia. Website: https://b-s-h.org.uk/media/18244/hbphccs-response-to-covid-v9-200420.pdf (Accessed: 23.04.2020)
  • 7. American Society of Hematology. COVID-19 and Thalassemia. Website: https://www.hematology. org/covid-19/covid-19-and-thalassemia (Accessed: 23.04.2020)
  • 8. European Hematology Association. Webinar Session 3: SCD/Thalassemia and COVİD-19. Possible Risks and a Proposal for a Patient Pathway During teh Pandemic. (Date 16 April 2020)
  • 9. Motta I, De Amicis MM, Pinto VM, Balocco M, Longo F, Bonetti F, et al. SARS-CoV-2 infection in beta thalassemia: preliminary data from the Italian experience. Am J Hematol. 2020 Apr 20. doi: 10.1002/ajh.25840. [Epub ahead of print]
  • 10. Ünal S. Orak Hücreli Anemi Tedavi ve İzlem. Türk Hematoloji Derneği, Hematolog 2014:4-1.
  • 11. Abboud MR. Standard management of sickle cell disease complications. Hematol Oncol Stem Cell Ther. 2020 Mar 12. pii: S1658-3876(20) 30026-1.
  • 12. Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med. 2017;376(16):1561-73.
  • 13. Strouse JJ, Reller ME, Bundy DG, Amoako M, Cancio M, Han RN, et al. Severe pandemic H1N1 and seasonal influenza in children and young adults with sickle cell disease. Blood. 2010 Nov 4;116(18):3431-4.
  • 14. Bundy DG, Strouse JJ, Casella JF, Miller MR. Burden of influenza-related hospitalizations among children with sickle cell disease. Pediatrics. 2010 Feb;125(2):234-43.
  • 15. Beerkens F, John M, Puliafito B, Corbett V, Edwards C, Tremblay D. COVID-19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient. Am J Hematol. 2020 Apr 3. doi: 10.1002/ ajh.25809. [Epub ahead of print]
  • 16. Nur E, Gaartman AE, van Tuijn CFJ, Tang MW, Biemond BJ. Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19). Am J Hematol. 2020 Apr 8. doi: 10.1002/ajh.25821. [Epub ahead of print]
  • 17. De Luna G, Habibi A, Deux JF, Colard M, d’Alexandry d’Orengiani ALPH, Schlemmer F, et al. Rapid and Severe Covid-19 Pneumonia with Severe Acute Chest Syndrome in a Sickle Cell Patient Successfully Treated with Tocilizumab. Am J Hematol. 2020 Apr 13. doi: 10.1002/ajh.25833. [Epub ahead of print]
  • 18. Secure SCD Registry. Surveillance Epidemiology of Coronavirus (COVID-19) Under Research European Exclusion. Website: https://covidsicklecell. org/ (Accessed: 23.04.2020)
Birincil Dil tr
Konular Diş Hekimliği, Eczacılık, Farmakoloji ve Eczacılık, Toksikoloji, Temel Bilimler, Tıp
Bölüm Derleme
Yazarlar

Orcid: 0000-0003-4109-2143
Yazar: Ali FETTAH (Sorumlu Yazar)
Kurum: SAĞLIK BİLİMLERİ ÜNİVERSİTESİ
Ülke: Turkey


Orcid: 0000-0002-8835-3235
Yazar: Zeynep KARAKAŞ
Kurum: İSTANBUL ÜNİVERSİTESİ
Ülke: Turkey


Tarihler

Yayımlanma Tarihi : 15 Mayıs 2020

APA FETTAH, A , KARAKAŞ, Z . (2020). COVID-19 ve Hemoglobinopatiler. Sağlık Bilimlerinde İleri Araştırmalar Dergisi , 3 (S1) , 63-67 . Retrieved from https://dergipark.org.tr/tr/pub/sabiad/issue/54344/738111